Live
Sickle cell disease
Sickle cell disease (SCD), also simply called sickle cell, is a group of inherited hemoglobin-related blood disorders. Sickle cell disease is caused by an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to the red blood cells adopting an abnormal sickle-like shape under certain circumstances. With this shape, they cannot deform as they pass through capillaries, causing blockages.
166trials recruiting now
United Statesmost trial sites (115)
334mapped site locations
St. Jude Children's Remost active sponsor
Trials by phase
Phase 1 tests safety, phase 2 tests whether it works, phase 3 compares it with standard care, phase 4 follows it after approval.
Countries with the most trials
Where trials are recruiting
Each dot is a site city; bigger dots have more recruiting trials. Showing up to 400 locations.
Lead sponsors
St. Jude Children's Research Hospital · 14National Heart, Lung, and Blood Institute (NHLBI) · 8Children's Hospital Medical Center, Cincinnati · 7Assistance Publique - Hôpitaux de Paris · 6Emory University · 4Washington University School of Medicine · 4Novartis Pharmaceuticals · 3Hospital Universitari Vall d'Hebron Research Institute · 3
Newest recruiting trials
- Not applicable (device/behavioral)
Virtual Reality for SCD VOC
- Phase 2
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
- Not applicable (device/behavioral)
Universal Newborn Screening For Sickle Cell Disease In Mozambique
- Phase 2
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
- Not applicable (device/behavioral)
Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing
- Phase 2
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
- Not applicable (device/behavioral)
Early Life Exposures Among Children With Sickle Cell Disease
- Phase 1
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease
- Phase 1
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
- Phase 4
Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
- Phase 3
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
- Phase 1, Phase 2
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- Phase 3
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
- Not applicable (device/behavioral)
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
- Phase 1, Phase 2
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
- Observational study
Functional Ovarian Reserve in Sickle Cell Disease
- Phase 1, Phase 2
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
- Observational study
Hydroxyurea Optimisation in Sickle Cell Disease
- Phase 2
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
- Not applicable (device/behavioral)
SickleFit Exercise and Nutrition Study
- Not applicable (device/behavioral)
Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening
- Phase 2
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
- Not applicable (device/behavioral)
Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
- Phase 1, Phase 2
Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
- Phase 2
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
See all 166 on ClinicalTrials.gov →
General information only, not medical advice. Trial listings are written by sponsors; eligibility and contacts are on each official listing.